Organon & Co.'s (OGN) "Sell (D+)" Rating Reiterated at Weiss Ratings

Key Points

• Organon & Co.'s stock has been given a "sell (D+)" rating by Weiss Ratings, signaling analyst concerns over the company's performance.
• Shares of Organon traded down to $10.18 with a market cap of $2.65 billion, reflecting a P/E ratio of 3.78.
• Despite a beat on earnings per share with $1.00 reported, the company's revenue declined by 0.8% year-over-year to $1.59 billion.

Organon & Co. (NYSE:OGN - Get Free Report)'s stock had its "sell (d+)" rating reiterated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Organon & Co. Stock Performance

Shares of OGN traded down $0.06 during trading hours on Wednesday, reaching $10.18. 89,534 shares of the company traded hands, compared to its average volume of 4,335,289. The stock's fifty day moving average is $9.89 and its 200 day moving average is $10.31. The stock has a market cap of $2.65 billion, a P/E ratio of 3.78, a price-to-earnings-growth ratio of 0.96 and a beta of 0.63. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $19.05.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the prior year, the business earned $1.12 earnings per share. The firm's revenue for the quarter was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA raised its position in Organon & Co. by 8.3% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock worth $159,553,000 after purchasing an additional 820,378 shares in the last quarter. State Street Corp raised its position in Organon & Co. by 6.0% in the second quarter. State Street Corp now owns 9,520,594 shares of the company's stock worth $92,159,000 after purchasing an additional 540,478 shares in the last quarter. LSV Asset Management raised its position in Organon & Co. by 6.1% in the first quarter. LSV Asset Management now owns 7,980,775 shares of the company's stock worth $118,834,000 after purchasing an additional 455,699 shares in the last quarter. Nordea Investment Management AB raised its position in Organon & Co. by 1.1% in the second quarter. Nordea Investment Management AB now owns 4,904,076 shares of the company's stock worth $48,281,000 after purchasing an additional 53,733 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in Organon & Co. by 136.1% in the second quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company's stock worth $31,507,000 after purchasing an additional 1,876,264 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.